The short version of anti-doping category fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-03 and is reviewed periodically as new material appears.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Freeze-dried cake or loose powder after lyophilization |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are less durable than the powder |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light; avoid repeated freeze-thaw cycles |
| Identity method | Electrospray mass spectrometry | Compared against the expected mass; paired with sequence or composition analysis |
| Purity method | Reverse-phase HPLC with ultraviolet detection | Reports main-peak percentage rather than peptide content by mass |
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
is not known. The other example, adenosine monophosphate is shown to illustrate the fact that a third species may, in principle, be involved. In fact the concentration of (AMP)H2+3 is negligible at the isoelectric point in this case. If the pI is greater than the pH, the molecule will have a positive charge.
mole (mol) A unit (symbol: mol) used to measure the amount of a substance in terms of the absolute number of particles or entities composing the substance. By definition, one mole of any substance contains exactly the Avogadro number (i.e. 6.022×1023) of particles or entities.
== External links == Woon, David E. (October 1, 2010). "Interstellar and Circumstellar Molecules". Retrieved 2010-10-04. "Molecules in Space". Universität zu Köln. April 2022. Retrieved 2022-05-25. Dworkin, Jason P. (February 1, 2007). "Interstellar Molecules". NASA's Cosmic Ice Lab. Retrieved 2010-12-23. Wootten, Al (November 2005). "The 129 reported interstellar and circumstellar molecules". National Radio Astronomy Observatory. Retrieved 2007-02-13. Lovas, F. J.; Dragoset, R. A. (February 2004). "NIST Recommended Rest Frequencies for Observed Interstellar Molecular Microwave Transitions, 2002 Revision". Journal of Physical and Chemical Reference Data. 33 (1): 177. Bibcode:2004JPCRD..33..177L. doi:10.1063/1.1633275. Archived from the original on 2013-02-01. Retrieved 2007-02-13. Williams, David A.; Cecchi-Pestellini, Cesare (8 February 2023). Astrochemistry: Chemistry in Interstellar and Circumstellar Space. Royal Society of Chemistry. ISBN 978-1-83916-939-7.
Among the projects that SASO set its members to conduct in the holidays were repairs to schools, house-building, and instructions on financial management and agricultural techniques. Healthcare was also a priority, with SASO members focusing on primary and preventative care.
=== Disadvantages === Reduced immunogenicity compared to attenuated vaccines Require adjuvants to improve immunogenicity Often require multiple doses ("booster" doses) to provide long-term immunity Can be difficult to isolate the specific antigen(s) which will invoke the necessary immune response It is not easy to supervise conjugation chemistry which leads to noncontinuous variation
Sources: en.wikipedia.org
=== High-resolution mass spectrometry (MS) and high-performance liquid chromatography (HPLC) === The most commonly applied methods are MS and HPLC, in which the glycan part is cleaved either enzymatically or chemically from the target and subjected to analysis. In case of glycolipids, they can be analyzed directly without separation of the lipid component. N-glycans from glycoproteins are analyzed routinely by high-performance-liquid-chromatography (reversed phase, normal phase and ion exchange HPLC) after tagging the reducing end of the sugars with a fluorescent compound (reductive labeling). A large variety of different labels were introduced in the recent years, where 2-aminobenzamide (AB), anthranilic acid (AA), 2-aminopyridin (PA), 2-aminoacridone (AMAC) and 3-(acetylamino)-6-aminoacridine (AA-Ac) are just a few of them. O-glycans are usually analysed without any tags, due to the chemical release conditions preventing them to be labeled. Fractionated glycans from high-performance liquid chromatography (HPLC) instruments can be further analyzed by MALDI-TOF-MS(MS) to get further information about structure and purity. Sometimes glycan pools are analyzed directly by mass spectrometry without prefractionation, although a discrimination between isobaric glycan structures is more challenging or even not always possible. Anyway, direct MALDI-TOF-MS analysis can lead to a fast and straightforward illustration of the glycan pool. In recent years, high performance liquid chromatography online coupled to mass spectrometry became very popular.
They invented a stochastic corrector model that assumed that replicative templates compete within compartments, and selective values of these compartments depend on the internal composition of templates. Numerical simulations showed that when stochastic effects are taken into account, compartmentalization is sufficient to integrate information dispersed in competitive replicators without the need for hypercycle organization. Moreover, it was shown that compartmentalized hypercycles are more sensitive to the input of deleterious mutations than a simple package of competing genes. Nevertheless, package models do not solve the error threshold problem that originally motivated the hypercycle.
Pneumatic nebulization of mobile phase from the analytical column forming an aerosol. Aerosol conditioning to remove large droplets. Evaporation of solvent from the droplets to form dried particles. Particle charging using an ion jet formed via corona discharge. Particle selection – an ion trap is used to excess ions and high mobility charged particles. Measurement of the aggregate charge of aerosol particles using a filter/electrometer. The CAD like other aerosol detectors, can only be used with volatile mobile phases. For an analyte to be detected it must be less volatile than the mobile phase. More detailed information on how CAD works can be found on the Charged Aerosol Detection for Liquid Chromatography Resource Center.
A common and popular fish for tropical freshwater aquaria, C. macracanthus is a visually pleasing species. Although specimens in the wild will reach 40 to 50 cm, in the aquaria it is uncommon for C. macracanthus to attain more than 15 to 20 cm fork length. They are a very long-lived species, living up to 30 years. These fish have bifurcated spines under the eyes. They are thought to be used as a defence mechanism and possibly, for obtaining prey. C. macracanthus will associate with other benthic species in the aquaria if kept singly or with few other specimens. They make suitable tank-mates for any non-aggressive community fishes, but do not thrive when kept with larger, more dominant species. Occasionally C. macracanthus will exhibit erratic swimming patterns, such as swimming on their sides or upside down. This is not usually a sign of illness, however, and the fish will typically resume normal behaviour almost instantly. As C. macracanthus is found in riverine environments it is able to cope with good flow rates of water in the aquaria. Aquascapes may replicate this environment to suit the requirements of the species with areas of high flow, but also typically include areas of low flow to allow the fish to rest. C. macracanthus is also fond of cover and is not overly accustomed to bright lighting. The fish will often seek areas of shade or cover in which to rest during the day and become more active when light levels are more subdued. The barbels of clown loaches are known to be easily damaged by rough substrates, such as gravel, in aquaria.
Sources: en.wikipedia.org
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.
It describes the share of the chromatographic signal belonging to the main peak, not the mass fraction of peptide in the vial. Water, counter-ions such as acetate or trifluoroacetate, and residual solvents account for part of the weight of a lyophilized lot. Peptide content by mass is a separate measurement and is often reported alongside purity.
Mass spectrometry is the primary check, because the measured mass can be compared with the expected value for the fifteen-residue chain. Sequence analysis or amino acid composition provides an independent confirmation. Purity testing alone does not establish identity, since a mixture of unrelated short peptides can still produce a clean-looking chromatogram.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.